Elon Musk and his Neuralink company's attempt to begin testing brain chips in humans has been rejected by the FDA, according to a report by Reuters.
The request was submitted to the agency last year but according to Reuters, the FDA identified several problematic factors with the technology, including the chip's lithium battery and the potential for small wires to move to other areas of the brain.
"Neuralink doesn't appear to have the mindset and experience that's needed to get this to market anytime soon," Kip Ludwig, former program director for neural engineering at the U.S. National Institute of Health.
There was also a concern of whether or not the chip could be removed without inflicting damage to brain tissue.
What Exactly Is Neuralink?
Musk has claimed the technology could be life-changing for people suffering from paralysis, enabling them to communicate and walk, or it could help repair visual impairment in people.
The chip is supposed to process brain signals that are then transmitted to a device. While human trials for Neuralink have not commenced, there have been versions of the tech that reportedly had some success in animals. However, the company faced pushback and a probe from the U.S. Department of Agriculture after animal cruelty concerns were raised.
Last month Neuralink admitted that at least one monkey was euthanized because of a surgical complication.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Scott Trench, host of the BiggerPockets Money Podcast, explores how recent rate cuts, high borrowing costs, and mortgage rates are reshaping U.S. real estate.
